Inventor

RAMMENSEE HANS-GEORG

DE83 patents

⚠️ This page may combine multiple inventors who share the name “RAMMENSEE HANS-GEORG”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

RAMMENSEE HANS-GEORG

IMMATICS BIOTECHNOLOGIES GMBH

Powerful MHC-class II peptides derived from survivin

Tumor-associated peptides that bind to MHC-molecules

Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers

Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)

Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)

Tumour-associated peptides binding to MHC-molecules

Tumour-associated peptides binding to MHC-molecules

Tumor-associated peptides binding to MHC-molecules

Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers

Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers

Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers

Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers

Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers

Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers

Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers

Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers

Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers

Method for identifying and quantifying of tumuor-associated

Powerful MHC-class II peptides derived from survivin

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)

Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)

Cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancers

Cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancers

Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)

Peptide for triggering an immune reaction against tumor cells

Peptide for triggering an immune reaction against tumor cells

Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers

Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers

Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)

Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)

Method for identifying immunoreactive peptides

Cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancers

Peptides and combination thereof for use in the immunotherapy against cancers

Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers

RAMMENSEE HANS-GEORG

Powerful MHC-class II peptides derived from survivin

Powerful MHC-class II peptides derived from survivin

Immunogenic T-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes

WEINSCHENK TONI

Tumour-associated peptides that bind to MHC molecules

Tumour-associated peptides that bind to MHC molecules

HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof

LUDWIG INST CANCER RES

Isolated peptides consisting of amino acid sequences found in SSX or NY-ESO-1 molecules, which bind to HLA molecules

Nonapeptides that bind a HLA-A2.1 molecule

HOECHST AG

Membrane anchor/active compound conjugate, its preparation and its uses

MAX PLANCK GESELLSCHAFT

Determination of peptide motifs on MHC molecules